The International Association for the Study of Lung Cancer (IASLC), has recently announced ten new expert additions to its Board of Directors. Joining the nine other renowned thought leaders who pioneer research against lung cancer – Clarissa Mathias, James Yang, Suresh Ramalingam, Anne Fraser, Paul Van Schil, Yuko Nakayama, Masayuki Noguchi, Julie Brahmer and Takashi Seto, is Enriqueta Felip, Principal Investigator of VHIO´s Thoracic Tumors & Head and Neck Cancer Group, Specialist Physician in Medical Oncology at the Vall d´Hebron University Hospital (HUVH), and Head of the Medical Oncology Service of the Thoracic Tumors Committee of the same hospital.
Voted in by the Association´s members, Enriqueta will serve IASLC by imparting her expertise in lung cancer and other thoracic malignancies and assuming a key role in effectively enhancing the development of existing IASLC programs and committees set firmly within the context of precision medicine. She will also seek to strengthen multidisciplinarity and promote cross border translational science in collaboration.
Founded back in 1074, IASLC is the only global organization dedicated to the study of lung cancer and currently counts an international membership of over 5,000 lung cancer specialists spanning some 100 countries.
Sharing the same commitment as the Association´s members, namely, advancing the understanding of lung cancer among researchers, clinical investigators, members of the medical community and the public at large, Enriqueta´s second to none dedication to not only driving novel drug development and significantly advancing novel treatment approaches including immunotherapeutics and liquid biopsy, will undoubtedly contribute to delivering on the Association´s mission of ´using all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world´.
“I am truly honored to have been elected to join IASLC´s Board of Directors. To be called upon to help steer the Association towards the future in this exciting and promising era of transformative medicine against cancer really is a privilege. As such, I am exceedingly grateful to all those members who voted for me and would like to thank each and every one of them for entrusting in me”, commented Enriqueta.
As a reflection of Enriqueta´s leadership and internationally recognized research of excellence, she has served on many other boards and committees including the European Society of Medical Oncology´s (ESMO) Guidelines Committee, ESMO´s European Lung Cancer Conference Scientific Committee, the Executive Committee of the Spanish Lung Cancer Group (GECP), and the Board of Directors of the Spanish Society for Medical Oncology (SEOM). She currently serves as appointed Member of ESMO´s Lung Faculty Group.
To discover more about IASLC please visit: www.iaslc.org